Cilostazol
Noclaud, containing the active ingredient cilostazol, belongs to a group of medicines called phosphodiesterase type 3 inhibitors. It has various effects, including the dilation of certain blood vessels and the reduction of the activity of blood clotting (aggregation) of certain blood cells, called platelets, within blood vessels.
Noclaud has been prescribed to treat "intermittent claudication". Intermittent claudication is a type of cramp-like pain in the lower limbs that occurs during walking, which is caused by insufficient blood flow to the legs. Noclaud increases the distance that a patient can walk without experiencing pain, by improving blood circulation in the lower limbs.
Cilostazol is recommended only for patients for whom lifestyle modifications (including smoking cessation and increased exercise intensity) and other appropriate interventions have not sufficiently alleviated symptoms. It is essential that patients continue to implement lifestyle modifications during cilostazol treatment.
Before starting treatment with Noclaud, discuss it with your doctor or pharmacist:
During treatment with Noclaud:
Noclaud is not intended for children.
Tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
In particular, inform your doctor about taking certain medicines that are usually used to treat pain and/or inflammation of muscles or joints, as well as medicines that reduce blood clotting. These include:
If such medicines are taken together with Noclaud, the doctor may perform certain routine blood tests.
Some medicines taken at the same time as Noclaud may interfere with its action. They may enhance the side effects of Noclaud or reduce its effectiveness. Noclaud may similarly affect other medicines. Before starting treatment with Noclaud, inform your doctor about taking:
In case of doubt whether the above applies to the medicines taken by the patient, consult a doctor or pharmacist.
Before starting treatment with Noclaud, the patient should inform the doctor if they are taking medicines for high blood pressure, as Noclaud may cause additional blood pressure-lowering effects. If excessive blood pressure lowering occurs, it may lead to rapid heart rate. These medicines include:
It is possible that the concurrent use of the above medicines and Noclaud will still be acceptable, and the doctor will be able to decide what treatment is appropriate for the patient.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor or pharmacist before taking this medicine.
Noclaud MUST NOTbe taken during pregnancy.
IT IS NOT RECOMMENDEDto take Noclaud during breastfeeding.
Noclaud may cause dizziness. If dizziness occurs after taking Noclaud, DO NOTdrive vehicles, do not use any tools, and do not operate any machinery. Inform the doctor or pharmacist.
This medicine should always be taken as directed by a doctor or pharmacist. In case of doubt, consult a doctor or pharmacist.
Noclaud is available in the following strengths: 50 mg, 100 mg.
Some benefits of taking Noclaud may be noticeable after 4-12 weeks of treatment.
The doctor will assess the effectiveness after 3 months of treatment and may recommend stopping cilostazol treatment if the therapy is not effective enough.
Noclaud is not intended for children.
If the patient has taken more Noclaud tablets than they should, they may experience objective and subjective symptoms, such as severe headaches, diarrhea, low blood pressure, and irregular heart rhythm.
In case of taking a higher dose than prescribed, contact a doctor or local hospital immediately. Remember to take the packaging with you to show which medicine was taken.
There is no reason to worry if a dose is missed. Wait and take the next dose at the right time, and then take the medicine as directed. DO NOTtake a double dose to make up for the missed tablet.
If treatment with Noclaud is stopped, the pain in the lower limbs may return or worsen. Therefore, treatment with Noclaud should only be stopped if side effects occur that require urgent medical attention (see section 4) or on the advice of a doctor.
In case of any further doubts about taking this medicine, consult a doctor or pharmacist.
Like all medicines, Noclaud can cause side effects, although not everybody gets them.
If any of the following side effects occur, urgent medical attention may be necessary. Stop taking Noclaud and contact a doctor or go to the nearest hospital.
Also, inform the doctor immediately if fever or sore throat occurs.
It may be necessary to perform certain blood tests, and the doctor will decide on further treatment.
(may affect more than 1 in 10 people)
(may affect up to 1 in 10 people)
(may affect up to 1 in 100 people)
In people with diabetes, there may be a higher risk of bleeding into the eye.
(may affect up to 1 in 1000 people)
During treatment with cilostazol, the following side effects have been reported, but their frequency is unknown
(the frequency cannot be estimated from the available data):
If any side effect worsens, inform the doctor or pharmacist.
If you experience any side effects, including any side effects not listed in this leaflet, inform your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 (22) 49 21 301, fax: +48 (22) 49 21 309, website: https://smz.ezdrowie.gov.pl
Reporting side effects will help gather more information on the safety of this medicine.
There are no special precautions for storage.
Keep the medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Do not use this medicine if you notice visible signs of deterioration (e.g., discoloration).
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Appearance:Odorless or almost odorless, white or almost white, round, flat tablets with beveled edges. The tablets have a stylized letter "E" and the number "602" embossed on one side, and no markings on the other side.
Packaging:56 tablets in PVC/PVDC/Al blisters in a cardboard box with an attached patient information leaflet.
For more detailed information, contact the marketing authorization holder or the parallel importer.
Egis Gyógyszergyár Zrt.
Keresztúri út 30-38.
H-1106 Budapest
Hungary
Egis Gyógyszergyár Zrt.
Bökényföldi út 118-120.
H-1165 Budapest
Hungary
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Marketing authorization number in Hungary, the country of export: OGYI-T-22586/04
Hungary
Noclaud 100 mg tablet
Czech Republic
Noclaud
Latvia
Sollazon 100 mg tablets
Lithuania
Sollazon 100 mg tablets
Poland
Noclaud
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.